Envoy Medical (COCH) Cash from Financing Activities (2021 - 2026)

Envoy Medical (COCH) has 6 years of Cash from Financing Activities data on file, last reported at $27.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 675.86% year-over-year to $27.6 million; the trailing twelve-month figure through Mar 2026 stood at $40.7 million (up 134.64% YoY), and the FY2025 full-year result was $16.6 million, down 17.65% from the prior year.
• Cash from Financing Activities advanced to $27.6 million in Q1 2026, from $6.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $27.6 million in Q1 2026 to a low of -$1.5 million in Q4 2023.
• A 5-year average of $5.5 million and a median of $4.0 million in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 76633.33% in 2022 and tumbled 172.7% in 2023, its largest moves.
• Tracing COCH's Cash from Financing Activities over 5 years: stood at $2.0 million in 2022, then slumped by 172.7% to -$1.5 million in 2023, then surged by 486.31% to $5.6 million in 2024, then rose by 7.53% to $6.0 million in 2025, then soared by 356.52% to $27.6 million in 2026.
• Business Quant data shows COCH's Cash from Financing Activities at $27.6 million in Q1 2026, $6.0 million in Q4 2025, and $2.6 million in Q3 2025.